Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -142,163 | 134,127 | 78,571 | 25,878 | 25,291 |
| Depreciation Amortization | 568,312 | 325,035 | 239,871 | 120,364 | 576,741 |
| Income taxes - deferred | -75,292 | -15,122 | -41,030 | -19,041 | -67,428 |
| Accounts receivable | 35,737 | 8,106 | -18,490 | -29,353 | 21,612 |
| Accounts payable and accrued liabilities | 2,869 | 40,747 | 16,241 | 25,251 | -14,271 |
| Other Working Capital | 14,081 | 7,309 | 12,454 | 1,287 | -30,329 |
| Other Operating Activity | 334,102 | 89,924 | 88,683 | 47,311 | 222,961 |
| Operating Cash Flow | $737,646 | $590,126 | $376,300 | $171,697 | $734,577 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -20,076 | -12,544 | -8,090 | -5,302 | -52,876 |
| PPE Investments | -219,152 | -130,202 | -77,181 | -41,883 | -232,967 |
| Net Acquisitions | 17,441 | 17,441 | N/A | N/A | -5,479 |
| Sale Of Investment | 9,102 | 5,637 | 2,106 | 1,602 | 41,687 |
| Other Investing Activity | 3,364 | 3,154 | 347 | 104 | 4,549 |
| Investing Cash Flow | $-209,321 | $-116,514 | $-82,818 | $-45,479 | $-245,086 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,227,534 | 1,070,861 | 963,363 | 416,341 | 1,081,581 |
| Debt Repayment | -1,349,317 | -1,141,500 | -887,706 | -149,394 | -1,493,769 |
| Common Stock Issued | 714 | 3 | 1 | 0 | 23,878 |
| Common Stock Repurchased | -360,673 | -360,577 | -360,484 | -353,132 | -119,175 |
| Other Financing Activity | -54,984 | -53,649 | -47,420 | -19,140 | -43,442 |
| Financing Cash Flow | $-536,726 | $-484,862 | $-332,246 | $-105,325 | $-550,927 |
| Exchange Rate Effect | 18,828 | 14,900 | 17,934 | 5,265 | -17,474 |
| Beginning Cash Position | 205,570 | 205,570 | 205,570 | 205,570 | 284,480 |
| End Cash Position | 215,997 | 209,220 | 184,740 | 231,728 | 205,570 |
| Net Cash Flow | $10,427 | $3,650 | $-20,830 | $26,158 | $-78,910 |
| Free Cash Flow | |||||
| Operating Cash Flow | 737,646 | 590,126 | 376,300 | 171,697 | 734,577 |
| Capital Expenditure | -219,152 | -130,202 | -94,622 | -59,324 | -232,967 |
| Free Cash Flow | 518,494 | 459,924 | 281,678 | 112,373 | 501,610 |